Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 30;10:16117. doi: 10.1038/s41598-020-73008-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Specificity of the GPR35 response to LNT and 6′SL. (a) HPAEC/PAD analysis of 6′SL and LNT before (black trace) and after (blue trace) treatment with Neuraminidase (6′SL) or β-galactosidase (LNT) showing complete digestion of the 6′SL and near complete digestion of LNT. The identities of the peaks are indicated. Gal, Galactose; DP3, agalacto-LNT; LNT, Lacto-N-tetraose; 6′SL, 6′Sialyllactose; NeuAc, N-Acetylneuraminic acid. nC: nanocoulomb. (b) Response of GPR35 to digested and undigested mix of LNT and 6′SL showing a response with the undigested mix and background response to the digested mix, thereby demonstrating the specificity of the GPR35 response. (c) Response of GPR35 to its agonist Zaprinast plus digested HMOs, showing only partial decrease of the GPR35 response to Zaprinast by the HMO digestion product.